AR066783A1 - Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica - Google Patents

Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica

Info

Publication number
AR066783A1
AR066783A1 ARP080102287A ARP080102287A AR066783A1 AR 066783 A1 AR066783 A1 AR 066783A1 AR P080102287 A ARP080102287 A AR P080102287A AR P080102287 A ARP080102287 A AR P080102287A AR 066783 A1 AR066783 A1 AR 066783A1
Authority
AR
Argentina
Prior art keywords
stable
muscle relaxant
providing
neurotoxic component
temperature based
Prior art date
Application number
ARP080102287A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR066783A1 publication Critical patent/AR066783A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion proporciona un proceso para proporcionar un relajante muscular, a temperaturas por encima de 6°C, con preferencia por encima de 25°C, donde dicho relajante muscular es una solucion reconstituida que comprende el componente neurotoxico de toxina botulínica libre de proteínas formadoras de complejos, el cual exhibe por lo menos una de las siguientes características, con más preferencia todas las características de la a) a la d): a) Es estable a temperaturas de almacenamiento por encima de 20°C, b) Es estable en presencia de conservantes y/o analgésicos, c) Es resistente contra ciclos de ôcongelacion y descongelacionö, d) Es estable si se almacena en envases de diferentes materiales.
ARP080102287A 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica AR066783A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
AR066783A1 true AR066783A1 (es) 2009-09-09

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102287A AR066783A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica
ARP080102286A AR066782A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080102286A AR066782A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida

Country Status (15)

Country Link
US (2) US20090028906A1 (es)
EP (2) EP2170375A1 (es)
JP (2) JP2010529000A (es)
KR (2) KR20100020971A (es)
CN (2) CN101687018A (es)
AR (2) AR066783A1 (es)
AU (2) AU2008256418A1 (es)
BR (2) BRPI0812245A2 (es)
CA (2) CA2686642A1 (es)
IL (2) IL202129A0 (es)
MX (2) MX2009012570A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145359A1 (es)
ZA (2) ZA200907874B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
PL2379104T3 (pl) 2008-12-31 2018-07-31 Revance Therapeutics, Inc. Preparaty toksyny botulinowej do wstrzykiwania
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
BRPI1008885B1 (pt) * 2009-02-19 2021-09-28 Merz Pharma Gmbh & Co. Kgaa Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
AU2010265888A1 (en) * 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
MX365496B (es) * 2009-10-21 2019-06-05 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
SG10202013124XA (en) * 2011-03-31 2021-02-25 Medy Tox Inc Lyophilized preparation of botulinum toxin
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
TWI669129B (zh) * 2014-12-23 2019-08-21 德商梅茲製藥有限兩合公司 預填充式玻璃容器及其套組與使用
KR102627068B1 (ko) * 2015-02-03 2024-01-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
ES2479515T3 (es) * 2004-07-26 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Composición terapéutica con una neurotoxina botulínica
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
JP4879978B2 (ja) 2005-06-17 2012-02-22 メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー 生物活性化合物を発酵生産するための装置及び方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
CA2686642A1 (en) 2008-12-04
ZA200907874B (en) 2011-03-30
US20090010965A1 (en) 2009-01-08
RU2009149604A (ru) 2011-07-20
MX2009012990A (es) 2010-04-01
WO2008145359A1 (en) 2008-12-04
IL202130A0 (en) 2010-06-16
TW200902050A (en) 2009-01-16
JP2010528999A (ja) 2010-08-26
TW200914039A (en) 2009-04-01
AR066782A1 (es) 2009-09-09
IL202129A0 (en) 2010-06-16
CA2686637A1 (en) 2008-12-04
CN101687018A (zh) 2010-03-31
KR20100020971A (ko) 2010-02-23
BRPI0812322A2 (pt) 2014-11-25
MX2009012570A (es) 2010-03-15
US20090028906A1 (en) 2009-01-29
WO2008145358A1 (en) 2008-12-04
AU2008256419A1 (en) 2008-12-04
KR20100020972A (ko) 2010-02-23
AU2008256418A1 (en) 2008-12-04
JP2010529000A (ja) 2010-08-26
EP2170375A1 (en) 2010-04-07
CN101720331A (zh) 2010-06-02
BRPI0812245A2 (pt) 2014-10-21
EP2164861A1 (en) 2010-03-24
ZA200907875B (en) 2010-11-24

Similar Documents

Publication Publication Date Title
AR066783A1 (es) Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica
TR200706710U (tr) Elektroluminesans donatılmış eşya.
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
AR108759A1 (es) Aceros de alto manganeso criogénicos de alta resistencia y métodos de fabricación de los mismos
WO2006134190A8 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
TW200606210A (en) Polythiophene formulations for improving organic light-emitting diodes
BR112014003462A2 (pt) artigos para cuidados pessoais tendo múltiplas zonas com composições para cuidados pessoais maleáveis
BRPI0716296A2 (pt) 'composição, artigo, estrutura laminada,dispersão,artigo moldado por injeção ,artigo moldado ,artigo para calçados e peça automotiva
BRPI0910964A2 (pt) método para tratamento da superficie de calçados, bolsas, luvas, outros artigos de couro ou artigos tipo couro, e, aparelho para impregnação de artigos
EP2350252A4 (en) ANTIMICROBIAL FOAMABLE SOAPS
TW200644719A (en) OLEDs utilizing direct injection to the triplet state
CL2019000054A1 (es) Procedimiento para la fabricación de briquetas que contienen un compuesto de calcio y magnesio y un compuesto a base de hierro, y briquetas así obtenidas.
BRPI0607782A2 (pt) misturas aditivas para artigos agrìcolas
GB2456466A (en) Sanitizing surfaces
MY172157A (en) Thioninium compounds and their use
WO2011080192A3 (en) A refrigerator comprising a door shelf
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
BR112014007306A2 (pt) artigos extrudados homogêneos feitos a partir de poliuretanos termoplasticamente processáveis com base em poliéster-dióis formados a partir de ácido succínico e de 1,3-propanodiol
DE602006009382D1 (de) Niedrigtemperaturdeckschicht
WO2010039819A3 (en) Compositions for use in identification of fungi
BRPI0515476A (pt) maço com preservação do frescor para artigos oblongos
BR112015027735A8 (pt) componente automotivo compreendendo material compósito
TR200904037T1 (tr) Bir soğutucu.
AR073562A1 (es) Articulo resistente a la penetracion
BR112018069771A2 (pt) copolímero de etileno/1-hexeno que possui capacidade de processamento e propriedades mecânicas excelentes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal